Emerging markets series: Benchmarking key countries Brazil, Russia, India, China and Turkey

Published by: Datamonitor

Published: Jan. 9, 2008 - 407 Pages

Table of Contents

CHAPTER 1 EXECUTIVE SUMMARY

Scope of the report

IMS caveat

Scorecard for analyzed countries

Patient potential in key emerging markets

Socioeconomic trends and business environment in key emerging markets 6

Health system dynamics

Pricing and reimbursement environment

Regulatory environment in key emerging markets-uncertainties exist but do not present major hurdles

Pharmaceutical market dynamics

CHAPTER 2 THE PHARMACEUTICAL MARKET IN BRAZIL

Tight pricing control is a downside but the overall environment and healthcare provision is improving

Demographic trends in Brazil

Disease burden is similar to the Western countries

Socioeconomic environment in Brazil - a land of inequality

Political climate is stable

Brazilian economy is growing at a moderate but steady level

Regional differences are great

Mercosur-the common market of South America

There is an abundant semi-skilled and unskilled workforce but the educational level is low

Business environment in Brazil-regulation and bureaucracy are considerable

Business entities

Taxation system is complex

Foreign direct investment in Brazil is growing

Importation is costly and laborious but export is incentivized

The healthcare system in Brazil is based on a public-private mix

Healthcare expenditure in Brazil

The public sector - the Unified Health System (SUS)

The private sector is restricted to the rich

After years of focus on hospital care, primary care is now predominant

Regulatory issues in Brazil

Intellectual property protection: long delays exist

Compulsory licenses on HIV/AIDS drugs were used only as a threat until May 2007

Registration of drugs-regulatory requirements are tightening

Imported pharmaceuticals have to be registered with ANVISA

Counterfeit drugs present a problem but a crackdown has started

Pricing and reimbursement of drugs in Brazil

Multiple mechanisms ensure tight price control on pharmaceuticals

Prices of marketed pharmaceuticals are controlled through price freezes and increases

Anti-retroviral drugs are priced low

Reimbursement is limited but is expected to improve

Patients are turning to courts to ensure they receive new treatments

Pharmaceutical market dynamics in Brazil

Distribution: a highly fragmented market

Brazil has a high number of pharmacies

Top manufacturers on the Brazilian retail market

Top ATC groups by sales value on the Brazilian retail pharmaceutical market

Top brands on the Brazilian retail market

Hospital sales of pharmaceuticals in Brazil

Advertising, marketing and sales of drugs

Major foreign pharmaceutical companies in Brazil

Sanofi-Aventis

Novartis

Bayer Schering

Pfizer

Boehringer-Ingelheim

It is difficult for multinational companies to enter the generics market

Major domestic pharmaceutical companies in Brazil

The generics market is dominated by a small number of leading companies

EMS

Medley

Eurofarma

Group Castro Marques (Biolab)

Ache Biosintetica

Drug manufacturing in Brazil

Multinational companies are ramping up export of drugs from Brazil but domestic companies are lagging behind

State-owned drug manufacturing is focused on antiretroviral drugs for HIV/AIDS

Investment in R&D in Brazil is growing

Phytopharmaceuticals-a new opportunity for Brazilian companies?

Clinical trials in Brazil

CHAPTER 3 THE PHARMACEUTICAL MARKET IN RUSSIA

The new reimbursement system and growing out-of-pocket spend have resulted in fast growth of the Russian pharmaceutical market

Demographic trends in Russia

Basic facts

Life expectancy is surprisingly low

Ageing and depopulation are resulting from declining birth rates

Disease burden in Russia

Socioeconomic environment in Russia

Political climate in Russia

Russia remains a centralized country with the center of power in Moscow

Economic environment in Russia: GDP and disposable income are growing

The Russian economy is trying to break away from overdependence on natural resources and is diversifying

Large regional differences exist

Accession to WTO is expected to bring positive changes

The labor market in Russia

The population is highly educated but the output is low

Looming labor shortage

Business environment in Russia-corruption and lack of transparency create difficulties

Foreign direct investment in Russia is mostly in the natural resource industry

Corruption is widespread

Excessive bureaucracy-red tape

Registration of a legal entity in Russia is a long and costly procedure

Taxation differs for foreign companies

Pharmaceuticals are subject to a reduced VAT rate of 10%

Customs duties are slowly becoming in line with the WTO

Healthcare system in Russia

Mandatory health insurance was introduced in 1991

Certain diseases have become a priority of the Russian government

The healthcare reform of 1991 signaled the privatization of healthcare

Healthcare expenditure is below the level of Western EU countries

Increased funding for healthcare is one of the priorities of the government

Primary versus hospital healthcare in Russia-focus on hospital care

'Under the table' expenditure is high in Russia

Access to healthcare is especially problematic for the poor population

Companies offering private health insurance are scarce and focus on the top end of the market

Regulatory issues in Russia

Intellectual property protection-several key issues remain unresolved

Patents ( insufficient enforceability of patent laws is a problem

Data exclusivity remains an unresolved issue

Drug counterfeiting in Russia

Registration of drugs in Russia

Certification of drugs is cumbersome but is used to detect counterfeit drugs

A large proportion of drugs are sold without prescription

Pricing and reimbursement of drugs in Russia

Pricing of drugs-few restrictions exist

Reimbursement-federal and regional lists exist

Certain drugs used in hospitals are funded by regional health budgets

Introduction of the federal reimbursement system DLO was a major change

The DLO program ( growing pains?

Drug price cuts and changes to the reimbursement list failed to keep DLO spending within the allocated budget

Insufficient planning for demand is putting a strain on the DLO program

State is becoming a bigger purchaser of drugs

The future of DLO program

DLO will be split into two programs in 2008

Pharmaceutical market dynamics in Russia

The distribution sector is fragmented but is consolidating

Foreign investment in the sector is increasing

The pharmacy networks sector is fragmented

Global pharma lead the Russian pharmaceutical market by sales value

Generics dominate the market in volume terms but account for only a fraction of the sales value

The retail market segment is growing at a steady rate

Top brands in the retail market segment in Russia

Top ATC groups by sales in the retail sector in Russia

Top manufacturers on the Russian retail market

The hospital market segment in Russia

Multinational companies dominate the hospital segment

Systemic antibacterials are the best selling therapeutic class

Consumption of expensive medicines is increasing in the hospital segment

The DLO program is one of the major growth drivers of the Russian pharmaceutical market but faces stagnation

Antineoplastic and immunomodulating agents were the best selling group in the DLO program in 2006

DLO has failed to increase the share of domestic producers and foreign manufacturers dominate

The top brands list in the DLO segment in 2006 is dominated by foreign brands

The establishment of the DLO drove the growth of the oncology sector

The DLO segment faces stagnation in 2007

Drugs can be imported into Russia through different channels

Top ATC groups of imported drugs

Top imported brands in Russia

Top foreign manufacturers by sales of imported drugs

The Russian pharmaceutical market will continue to grow

Export of pharmaceuticals from Russia is low

Launch, marketing and branding in Russia

Branding is important in Russia

Advertising of pharmaceuticals in Russia

Merck's co-marketing deal with Otechestvennie Lekarstva ( a first of its kind

Innovative drugs have the best market potential in Russia

Market entry strategies: acquiring a domestic producer?

Major foreign pharmaceutical companies on the Russian market

Sanofi-Aventis is the top foreign pharmaceutical company in Russia

Novartis's presence in Russia is growing

Servier

Roche

Gedeon Richter

Nycomed

Eli Lilly

Novo Nordisk

Bayer Schering

Actavis has strengthened its position in the Russian market through the acquisition of ZIO Zdorovie

Stada has increased its presence in the Russian market through three different entities

Major domestic pharmaceutical companies on the Russian market

Pharmstandard

Veropharm

Domestic producers will grow

Innovation is lagging behind the West

Manufacturing drugs in Russia

Clinical trials in Russia: a growing opportunity

CHAPTER 4 THE PHARMACEUTICAL MARKET IN INDIA

Improved patent protection environment fails to deliver on its promise but economic growth keeps the potential alive

Demographic trends in India: a trend toward ageing and urban population growth

Disease burden in India

Socioeconomic environment in India

Political climate in India - open to economic liberalization

Economic growth is steady and is concentrated in mid-sized and small urban centers

Poverty is declining for the first time since independence

Middle class income population is booming

Inadequate infrastructure is a major obstacle to faster growth

India is a member of the World Trade Organization

India has a high number of educated scientists

Business environment in India

India is opening up to Foreign Direct Investment

Legal entities in India

Corporate taxes in India are high but R&D incentives are given

Indirect taxes are very high in India and create a barrier for foreign companies

The central excise duty charging system was changed in 2005

Value added tax (VAT) was introduced in 2005 in India

Import tariffs are high in India

Export is encouraged through subsidies and special economic zones

Transparency and corruption in India

Healthcare system in India

Public health expenditure is low in India

Alternative medicine-AYUSH

Only a small fraction of the population has social security or private health insurance

Access to healthcare is poor especially in rural regions

Public health programs in India

Regulatory issues in India

Intellectual property protection in India is insufficient

Case study: Glivec was refused patent protection on the basis that incremental innovation is not patentable

Case study: AstraZeneca's patent application for Iressa was also rejected

Pfizer's maraviroc patent was granted - a change of tide for IP environment

India is benefiting from compulsory licenses for HIV/AIDS drugs in other countries

India is a major source of counterfeit drugs

Registration of drugs in India is straightforward

Importation of pharmaceuticals into India

Pricing and reimbursement of drugs in India

Control on drug pricing is getting tighter and is threatening to reduce the growth of the Indian market

Prices of certain pharmaceuticals in India are subject to price controls

Prices of drugs not subject to price control are being increasingly monitored and capped

Only a small number of drugs in India are reimbursed

Pharmaceutical market dynamics in India

The distribution sector in India is highly fragmented

Retail pharmacy chains are starting to appear

Top manufacturers on the Indian retail market-domestic companies dominate

Anti-infectives and gastrointestinal drugs hold almost 50% of the total market

Top brands on the Indian pharmaceutical market

Export of drugs from India is growing

Major foreign pharmaceutical companies in India

GlaxoSmithKline

Sanofi-Aventis

Abbott Laboratories

Pfizer

Major domestic pharmaceutical companies in India

Ranbaxy

Cipla

Nicholas Piramal

Zydus Cadila

Sun Pharma

Alkem Laboratories

Lupin

Dr Reddy's

India is a major hub of drug manufacturing activity

India is developing its capacity for development and manufacturing of biosimilars

R&D activities are increasing in India

Clinical trials in India - a growing opportunity

CHAPTER 5 THE PHARMACEUTICAL MARKET IN CHINA

A growing economy is fuelling demand and its R&D potential is attracting investment

Demographic trends-the world's most populous country is ageing

Disease burden in China

Socioeconomic environment in China

Political climate-stable and supporting economic growth

China's economy continues to grow but remains over-reliant on exports

Fast economic growth has fueled China's energy demand

China's middle class is growing

China - a good education system

Business environment in China

Foreign direct investment is contributing to economic growth

Business entities in China

Taxation system in China

Corruption is widespread

The difference between Chinese and Western cultures and the language barrier are a difficulty

Healthcare system in China

Healthcare expenditure-growing but insufficient

Growing out-of-pocket spend is the main contributor to the rising healthcare expenditure

Healthcare reforms have resulted in lower healthcare utilization

Access to healthcare services is difficult and discriminatory against the poor and the rural population

The density of healthcare workers is low and the hospital facilities are in a great need of an overhaul

Health insurance coverage is increasing in both urban and rural areas but is insufficient

The introduction of the urban employee Basic Medical Insurance System has improved healthcare coverage in cities

Rural health insurance coverage is increasing but the benefits are insufficient

The unemployed may be offered a very basic health insurance

Traditional Chinese Medicine still plays a role in Chinese healthcare

Regulatory issues in China-an improving environment

Intellectual property protection-improving but still a way to go

New drug regulations have failed to improve the IP protection and to satisfy the global pharmaceutical industry

Compulsory license provision in China?

Counterfeit drugs represent a particular threat

Registration of drugs in China is a complex process

Priority review procedures have been put in place to tackle health crises

China has resorted to drastic measures to improve its safety record

Pressure from export partners is forcing China to introduce practical measures to improve safety record

Obtaining import drug licenses is a long and costly process

Traditional Chinese Medicine is not tightly regulated

Pricing and reimbursement of drugs in China

Price cuts of reimbursable drugs threaten to reduce profit margins of manufacturers

In order to reduce the healthcare cost burden for patients the government is imposing heavy price cuts

Prices of drugs sold in hospitals are over-inflated

Reimbursement is negotiated at local level

Pharmaceutical Catalog classification

Pharmaceutical market dynamics in China

The distribution system in China is complex

Sales of drugs through retail pharmacies are encouraged

Several large multinational companies are among the top drug manufacturers in China

Top ATC groups in China-anti-infectives remain at the top but their growth is slowing down

Top products on the Chinese hospital market

Major foreign pharmaceutical companies in China

Pfizer

AstraZeneca

Bayer Schering

Roche

Novartis

Sanofi-Aventis

GlaxoSmithKline

Major domestic pharmaceutical companies in China

Yangtze River Pharmaceutical Group

Jiangsu Hengrui Medicine Company

The Harbin Pharmaceutical Group

Drug manufacturing in China-GMP is improving but IP protection is insufficient for Western manufacturers

Several Chinese biotechnology companies already have biosimilars products on the Chinese market

Many multinational companies have opened R&D centers in China

Clinical trials in China - international interest is high

CHAPTER 6 THE PHARMACEUTICAL MARKET IN TURKEY

Low drug prices limit the market potential but the overall environment is improving

Demographic trends in Turkey

Disease burden in Turkey

Socioeconomic environment in Turkey

Political climate-the new government supports foreign investment in Turkey

Desired accession to the EU is a stimulant for economic growth

Turkey is a member of the WTO and has entered the Customs Union with the EU

Labor market in Turkey-lack of educated workforce

A large working age population

Educational level is low compared to the West

Business environment in Turkey

Foreign direct investment is low but is growing

Legal corporate entities in Turkey

Taxation is becoming investor-friendly

Turkey is in Customs Union with the EU

Foreign trade zones and free ports have special customs treatment and tax advantages

Corruption is present but the government is fighting against it

Healthcare system in Turkey - universal healthcare coverage is on its way

Access to healthcare is poor in rural regions

The Health Transformation Program is reforming healthcare and driving the growth of the pharmaceuticals sector

Primary and family care is important for provinces with traditionally poor access to healthcare

Private health insurance accounts for a very small percentage of the population

Expenditure on pharmaceuticals accounts for a high proportion of the healthcare spend

Regulatory issues in Turkey

IP and data exclusivity in Turkey-improved but still a way to go

Turkey is a source of counterfeit drugs

Registration and importation of drugs in Turkey

Pricing and reimbursement of drugs in Turkey

Reimbursement is available but criteria and decisions are not transparent

There is no rationalization of drug but may be introduced

Lack of transparency is a problem

Tight price controls have resulted in price decreases

Pharmaceutical market dynamics-tight pricing controls are stumping growth

Distribution is dominated by several large companies

Retail pharmacy chains are not permitted

Top ATC groups by sales value in Turkey

The top brands list in Turkey is dominated by foreign products

The top manufacturers list is dominated by foreign companies

Imported versus local drugs

Major foreign pharmaceutical companies in Turkey

Novartis

Sanofi-Aventis

Roche

GlaxoSmithKline

Pfizer

Bayer-Schering

Eli Lilly

Major domestic pharmaceutical companies in Turkey

Abdi Ibrahim

Zentiva has acquired a stake in Eczacibasi

Bilim Pharmaceuticals

Actavis acquired Turkey's Fako

Drug manufacturing in Turkey-an unexploited opportunity?

Export of pharmaceuticals from Turkey is low

Conducting clinical trials in Turkey

Registration of clinical studies-approval times may be shortened

Local CRO industry is starting to emerge

CHAPTER 7 BIBLIOGRAPHY

Publications and online articles

Conference literature

Datamonitor resources

Websites

Exchange rates

Suggested reading

APPENDIX

Russian Pharmaceutical Market: additional data

Domestic manufacturers on the Russian market

Retail market segment in Russia

Top 20 drug manufacturers in the retail segment

Top brands in the Russian retail market in 2006

The hospital market in Russia

Top manufacturers

Top brands in the hospital segment

The DLO market segment in Russia

Top manufacturers in the DLO segment

Top brands in the DLO segment

IMS Health sales data for the Russian pharmaceutical market

Top manufacturers on the Russian market

Top brands in Russia

Top ATC groups in Russia

IMS Health's MIDAS sales data audit

Glossary

List of Tables

Table 1: Scorecard for the pharmaceutical markets in Brazil, Russia, India, China and Turkey 5

Table 2: Key demographic indicators for Brazil, 2005

Table 3: Top mortality causes in Brazil, 2002

Table 4: Brazil's average annual growth rate of GDP and exports (%), 1986-2010

Table 5: Key economic indicators for Brazil, 1986-2006

Table 6: Healthcare expenditure indicators in Brazil, 2004

Table 7: Density of healthcare workers and hospital capacity in Brazil, 2000

Table 8: Growth of the Brazilian pharmaceutical market by volume (%), 2003-06

Table 9: Branded generics dominate the Brazilian pharmaceutical market, 2006

Table 10: Brazil - average cost of units sold, 2003-06

Table 11: Top 15 Drug manufacturers in Brazil, 2006

Table 12: Segmentation of the Brazilian retail pharmaceutical market by ATC group sales value, 2006

Table 13: Top 15 brands in Brazil, 2006

Table 14: Key demographic indicators for Russia, 2004-2006

Table 15: Life expectancy and healthy life expectancy in Russia compared to the seven major markets, 2002 and 2005

Table 16: Top causes of mortality in Russia, 2002

Table 17: Russia is experiencing a steady growth in GDP, 2001-06

Table 18: Disposable income is also growing in Russia, 2002-05

Table 19: Healthcare expenditure in Russia, 2004 and 2005

Table 20: Hospital and healthcare capacity in Russia, 2003

Table 21: Top 20 pharmacy networks in Russia, 2006

Table 22: Top 20 drug manufacturers by sales value in the Russian pharmaceutical market, 2005 and 2006

Table 23: Top 25 brands by pharmacy sales value on the Russian market, 2006

Table 24: Sales structure by ATC group on the retail market, 2006

Table 25: Top 15 ATC2 groups by pharmacy sales value in Russia, 2006

Table 26: Top 25 manufacturers in the retail segment of the Russian market by value, 2006

Table 27: Top 25 manufacturers in the hospital segment in Russia, 2006

Table 28: Sales within the hospital segment by ATC group, 2006

Table 29: Top 25 products by hospital sales in Russia, 2006

Table 30: Sales structure by ATC groups of the DLO market, 2006

Table 31: Top 15 ATC1 groups in the DLO segment according to Pharmexpert, 2006

Table 32: Top 25 manufacturers within the DLO segment in Russian by value, 2006

Table 33: Top 25 brands in the DLO segment in 2006

Table 34: Top 10 oncology products in Russia, January-September 2006

Table 35: Top 10 manufacturers in the oncology segment in Russia, January-September 2006

Table 36: Shares in import value of different groups of drug importers in Russia, 2005 and 2006

Table 37: Top 10 representatives of foreign manufacturers by drugs import value, 2006

Table 38: Top 25 importers by import value in 2006

Table 39: Top 15 ATC2 groups of imported drugs to Russia by value, 2006

Table 40: Top 25 drugs imported in Russia by sales value, , 2006

Table 41: Top 25 foreign drug manufacturers by sales value of their imported drugs regardless of the import route, 2006

Table 42: Top 10 domestic manufacturers in Russia according to Pharmexpert, 2006

Table 43: Key demographic indicators for India

Table 44: Top 10 causes of mortality in India, 2002

Table 45: Key economic indicators for India, 2003-06

Table 46: Public healthcare expenditure indicators, 2004

Table 47: Traditional and indigenous systems of medicine in India

Table 48: Types of medical centers in the Indian public health sector

Table 49: Density of healthcare workers in India is extremely low

Table 50: Top 25 drug manufacturers in India, 2006

Table 51: Market segmentation in India according to ATC groups

Table 52: Top 15 brands on the Indian retail market, 2006

Table 53: Export of pharmaceuticals from India is growing, 2001-02-2006-07

Table 54: Recent R&D deals between Indian and multinational companies

Table 55: Key demographic indicators for China, 2005

Table 56: Top 10 causes of mortality in China, 2002

Table 57: Key economic indicators for China, 2003-06

Table 58: Several ministerial-level agencies have varying degrees of health authority in China

Table 59: Key Chinese health expenditure indicators, 2004

Table 60: Healthcare worker density in China is insufficient

Table 61: Categories of drug applications submitted to the SFDA and their data protection periods

Table 62: Top 25 pharmaceutical companies in China, 2006

Table 63: Anti-infectives were the largest ATC group by revenue in 2006

Table 64: Top 25 brands in China, 2006

Table 65: Top 25 drug molecules by sales value in China, 2006

Table 66: Many multinational companies have engaged in R&D in China

Table 67: Basic population facts for Turkey, 2005

Table 68: Top causes of death in Turkey in 2002

Table 69: Turkey - economic indicators, 2005

Table 70: Key health expenditure indicators for Turkey, 2004

Table 71: Health worker density in Turkey, 2003

Table 72: Maximum wholesaler and pharmacy margins in Turkey are based on a regressive scale

Table 73: Consumption of medicines in Turkey (million boxes per year), 2000-06

Table 74: Market segmentation in Turkey by ATC group spend, 2006

Table 75: Top 20 pharmaceutical brands in Turkey, 2006

Table 76: Top 20 drug manufacturers in Turkey by value, 2006

Table 77: Exchange rates for national currencies

Table 78: Segmentation of the Russian pharmaceutical market in 2005

Table 79: Top domestic manufacturers in Russia by sales value in 2006

Table 80: Top 20 drug manufacturers by pharmacy sales value in the Russian commercial market in 2005 and 2006

Table 81: Top 20 manufacturers on the Russian hospital segment, 2005-06

Table 82: Top 20 brands in the hospital segment of the Russian market in 2006 according to Aston Consulting

Table 83: TOP 20 drug manufacturers by DLO consumption in 2005 and 2006

Table 84: Top 20 brands by pharmacy sales value in the DLO segment in 2005 and 2006

Table 85: Top 20 drug manufacturers on the Russian market, 2006

Table 86: Top 20 brands on the Russian pharmaceutical market, 2006

Table 87: ATC group spend in Russia, 2006

Table 88: IMS MIDAS audit (1 of 4)

Table 89: IMS MIDAS audit (2 of 4)

Table 90: IMS MIDAS audit (3 of 4)

Table 91: IMS MIDAS (audit 4 of 4)

List of Figures

Figure 1: Key macroeconomic factors and healthcare system characteristics impacting the pharmaceutical market in Brazil

Figure 2: Pharmaceutical market dynamics in Brazil: an attractive proposition for foreign companies

Figure 3: Retail pharmaceutical market in Brazil, 2002-2006

Figure 4: Comparison of market shares of different ATC groups between Brazil and the six major markets

Figure 5: Key macroeconomic factors and healthcare system characteristics impacting the pharmaceutical market in Russia

Figure 6: Pharmaceutical market dynamics in Russia

Figure 7: The Russian healthcare system includes many bodies both at the federation and regional level

Figure 8: Mandatory Health Insurance Fund financing in Russia, 2007

Figure 9: The DLO reimbursement chain

Figure 10: Size and segmentation of the Russian pharmaceutical market ($ billion), 2004-2005

Figure 11: Top six distributors in the Russian market, 2005-2006

Figure 12: Advantages and disadvantages of carrying out clinical trials in Russia

Figure 13: Key macroeconomic factors and healthcare system characteristics influencing the pharmaceutical market in India

Figure 14: Pharmaceutical market dynamics in India

Figure 15: Maximum retail prices of controlled drugs in India are calculated using a formula

Figure 16: The retail pharmaceutical market in India is growing faster than the country's GDP, 2003-06

Figure 17: Drug distribution network in India

Figure 18: The market share of different ATC groups in India differs substantially from the six major markets

Figure 19: Advantages and disadvantages of conducting clinical trials in India

Figure 20: Key macroeconomic factors and healthcare system dynamics in China

Figure 21: Key pharmaceutical market dynamics in China

Figure 22: Protection of pharmaceutical products in China with or without a patent, 2006

Figure 23: Key steps for drug approval in China, 2006

Figure 24: Drug reimbursement in China

Figure 25: The growth rate of the Chinese hospital market is slowing down, 2002-06

Figure 26: The growth of the Chinese market is driven largely by growth in value not volume, 2002-06

Figure 27: Drug distribution channels in China, 2006

Figure 28: The market share of the individual ATC groups differs significantly between China and the six major markets

Figure 29: Revenues of all ATC groups are growing but anti-infectives are slowing down

Figure 30: Advantages and disadvantages of conducting clinical trials in China

Figure 31: Key macroeconomic factors and healthcare system characteristics impacting the pharmaceutical market in Turkey

Figure 32: Pharmaceutical markets in Turkey

Figure 33: The drug approval process in Turkey is complicated and lengthy

Figure 34: Pharmaceutical market size in Turkey, 2002-2006

Figure 35: Positioning of different therapy groups on the Turkish market

Figure 36: The relative market shares of each ATC group differ substantially between Turkey and the six major markets, 2006

Figure 37: The size and segmentation of the pharmaceutical market in Russia, 2005-06

Figure 38: Russian pharmaceutical market, 2002-06

Abstract

Introduction

With dwindling growth rates observed in the major developed markets many pharmaceutical companies are turning towards emerging market countries in order to sustain their revenue growth. While some countries, with double digit growth rates present tremendous opportunities, there are also many obstacles that need to be overcome.

Scope

Review of the key macroeconomic trends and business environment in analyzed countries In-depth analysis of the healthcare system dynamics in key emerging markets Analysis of the pharmaceutical market dynamics in analyzed emerging markets Overview of the outsourcing opportunities for key emerging markets

Highlights

Fast economic growth, increasing economic and political stability coupled with tremendous patient potential and increased Westernization of lifestyle present new opportunities for global pharmaceutical companies. Despite problematic intellectual property protection high market potential is attracting most multinational pharmaceutical companies. Healthcare system characteristics differ greatly between different emerging market countries. Greater state participation in healthcare provision is observed in all markets although growing disposable income and out-of-pocket expenditure are contributing to market growth. The changing medical needs of the emerging countries are favoring multinational companies: sales of anti-infective agents are slowing down and cancer drugs, immunomodulatory and respiratory drugs among others are growing at fast rates. With increasing purchasing power consumer preference for expensive new treatments is growing.

Reasons to Purchase

Identify the key trends that are driving and resisting the growth of the pharmaceutical market in key developing countries Understand the macroeconomic factors and healthcare system characteristics impacting the pharmaceutical market in the analyzed countries Gain insight into current market dynamics and opportunities and challenges for foreign companies wishing to enter these emerging markets.

Please note, this file is delivered as a Zip file.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.